88991-53-1

Upstream product

• 402-67-5 3-fluoro-1-nitrobenzene 
• 683-60-3 sodium isopropylate 
• 75-30-9 2-iodo-propane 
• 554-84-7 meta-nitrophenol 
• 75-26-3 isopropyl bromide 

Downstream Products

• 41406-00-2 3-isopropoxyaniline 
• 55814-41-0 mepronil 
• 860585-54-2 3-isopropoxy-N,N-dimethyl-4-nitroso-aniline 
• 256425-12-4 N-(3-isopropoxyphenyl)acetamide 
• 860735-61-1 3-isopropoxy-N,N-dimethyl-aniline 
• 133040-77-4 LY 202769 
• 133040-68-3 LY 247348 
• 74699-48-2 2-amino-N-(3-isopropoxyphenyl)benzamide 

Relevant academic research and scientific papers

[Cp?RhCl2]2-catalyzed alkyne hydroamination to 1,2-dihydroquinolines

[Cp?RhCl2]2 catalyzes the formation of 1,2-dihydroquinolines from the reaction of two terminal alkynes and an aniline. This reaction is believed to proceed via an alkyne hydroamination followed by an alkyne insertion.

Method of treating cognitive disorders

The invention concerns cholecystokinin (CCK) antagonists useful in the treatment of cognitive disorders. Especially useful are CCKBantagonists such as CI-988.

CHEMICAL COMPOUNDS

Triazine derivatives of formula (I) or salts thereof, wherein R1 represents a halogen atom or a group selected from hydroxy; C1-8 alkyl C1-6 alkoxy; C1-3 alkoxy C1-3 alkoxy; phenoxy or phenyl C1-3 alkoxy, wherein the phenyl group is optionally substituted by a halogen atom or a group selected from C1-3 alkyl, C1.3 alkoxy, or hydroxy; fluoro C1-3 alkyl; cyano; -CO2R3, wherein R3 represents a hydrogen atom or a C1-4 alkyl group; - CONR4R5, wherein R4 and R5 each independently represents a hydrogen atom or a C1-4 alkyl group, or, together with the nitrogen atom to which they are attached, form a saturated 5- to 7- membered ring, which ring optionally contains one or more atoms selected from an oxygen or a sulphur atom, or a group selected from -NH- or -N(CH3)-; and R2 represents a hydrogen or halogen atom, or a group selected from hydroxy, C1-6 alkyl or C1-6 alkoxy; are inhibitors of the enzyme 5-lipoxygenase. Processes for preparing the triazine derivatives of formula (I) and compositions containing them are also described

3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof

Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic applic